Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RICHMOND, Va. , May 16, 2023 /PRNewswire/ -- Aetna Better Health of Virginia, a CVS Health company (NYSE: CVS), and Virginia Community Healthcare Association (VCHA) announced that Aetna provided a total of $7.3 million in value-based care incentive payments to 22 Federally Qualified Health Centers, also known as Community Health Centers, in Virginia.

Virginia Community Health Centers and Aetna Better Health Virginia team-up to improve cancer outcomes in under-resourced communities

The market has reservations about CVS' leverage and vertical integration efforts and thus, applies a [low] multiple of 8x earnings to the stock. The stock is undervalued and should be trading hands near $109 per share, which represents 60% upside from the current price.

CVS Health: Margins, Margins, Margins

Ares Capital

Healthpeak Properties Inc

CVS Health is famous for its retail pharmacies, but it's the company's growing health benefits management business that makes it a great stock for retired investors. Physicians Realty Trust is a real estate investment trust that owns lots of medical office buildings.

3 Exceptional Dividend Stocks That Retirees Should Love

CVS Health delivered robust top-line growth in the first quarter. The company's market-beating dividend should keep rising.

1 Deeply Undervalued Dividend Stock to Buy in May

CVS Health Corporation (NYSE:CVS ) 2023 Bank of America Securities Health Care Conference Call May 10, 2023 11:40 AM ET Company Participants Shawn Guertin - Executive Vice President and Chief Financial Officer Conference Call Participants Mike Cherny - Bank of America Mike Cherny Thanks everyone for joining us for this session of the BofA Healthcare Conference. Mike Cherny, the Healthcare Tech and Distribution Analyst.

CVS Health Corporation (CVS) Presents at 2023 Bank of America Securities Health Care Conference Call Transcript

CVS is undervalued and generates impressive cash flow, but it faces competition, regulatory challenges, and low operating margins, resulting in mediocre returns on capital. Before investing, I believe an investor should study the complex operations behind the storefront of CVS before falling for its cash flow yield.

CVS: A High Cash Flow Yield, But A Low Return On Capital

Cigna

Eli Lilly

Novo Nordisk

Sanofi

UnitedHealth Group

A bipartisan effort to rein in prescription drug prices advanced Thursday as a key U.S. Senate committee approved a bill aimed at reforming pharmacy benefit managers.

Prescription-drug costs in spotlight as pharmacy benefit reform advances in Senate

In 2023, CVS stock lost significant value. Some investors have experienced a dreaded "round trip." CVS Health had a good glide path in a stay-pat mode; however, management had other ideas.

CVS Health: Investors Getting A Bellyache

CVS Health stock (NYSE: CVS) is down 5% in a month, underperforming the broader markets, with the S&P500 down 1%.

Should You Buy CVS Stock At $70?

CVS Health stock was already down this year before falling further in response to a first-quarter earnings call on May 3. The company lowered its earnings outlook for 2023, but management still expects to report significant earnings growth over the next couple of years.

CVS Health Is a Screaming Buy on the Dip

Procter & Gamble

Sempra Energy

Waste Management

Five Below

Home Depot

Progressive

Although I'm not trying to alarm anyone, investors may want to consider so-called crash-proof stocks. These are enterprises that enjoy both analyst support and command reliable, predictable businesses.

7 Must-Buy Stocks to Create a Crash-Proof Portfolio

U.S. Bancorp

Shares of CVS Health and U.S. Bancorp are both trading near their 52-week lows. Yet, both remain in good shape and potentially able to increase their dividends.

2 High-Yielding Dividend Stocks Analysts Expect Will Rise by at Least 50%

WOONSOCKET, R.I. , May 4, 2023 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced that Executive Vice President and Chief Financial Officer Shawn Guertin will participate in fireside chats with investors at the 2023 Bank of America Securities Health Care Conference on May 10, 2023, at approximately 8:40 a.m.

CVS Health to present at the 2023 Bank of America Securities Health Care Conference and at Bernstein's 39th Annual Strategic Decisions Conference

CVS Health's (CVS) robust sales growth across all three operating segments drives top-line results.

CVS Health (CVS) Q1 Earnings Surpass Estimates, EPS View Cut

Walgreens

Shares of Walgreens Boots Alliance Inc. WBA slumped 3.4% toward a six-week low, on the heels of CVS Health Corp.'s CVS earnings report in which the fellow health care services and drugstore chain cut its full-year profit outlook. Walgreens' stock, which paced the Dow Jones Industrial Average's DJIA declines, has dropped 8.2% amid a three-day losing streak.

Walgreens stock falls to lead the Dow's losers, after rival CVS cut its full-year profit outlook

The headline numbers for CVS Health (CVS) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

CVS Health (CVS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

CVS Health is progressing in creating a more robust omnichannel offering, ending the first quarter of 2023 by completing important strategic acquisitions and streamlining its growing ecosystem to better focus on streamlined customer experience across its services. During its first quarter 2023 earnings call on Wednesday (May 3), the Woonsocket, Rhode Island-based operator of over 9,600 U.S.

CVS Health Says 50 Million Digital Customers Spend 2.4X More Than In-Store Shoppers

Boeing

Chevron

Blue-chip stocks to watch for your long-term portfolio.

Best Long-Term Stocks To Buy Now? 3 Blue Chip Stocks In Focus

CVS Health Corporation (NYSE:CVS ) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Larry McGrath - SVP, Business Development and IR Karen S. Lynch - President and CEO Shawn M.

CVS Health Corporation (CVS) Q1 2023 Earnings Call Transcript

CVS Health Corp (NYSE:CVS) reported first quarter results that beat Wall Street's expectations, but the stock moved lower after the healthcare titan downwardly revised its full-year profit guidance.   The drugstore chain said it now expected adjusted earnings per share between $8.50 and $8.70 for full-year 2023, down from its earlier forecast of $8.70 to $8.90 and below the Street's forecast per a FactSet survey of $8.76.

CVS 1Q earnings top expectations but stock falls on lowered profit outlook

CVS Health (CVS) came out with quarterly earnings of $2.20 per share, beating the Zacks Consensus Estimate of $2.07 per share. This compares to earnings of $2.22 per share a year ago.

CVS Health (CVS) Tops Q1 Earnings and Revenue Estimates

CVS Health reported more than $2 billion in quarterly profits buoyed by more than 1 million new health plan members.

CVS Profits Surpass $2 Billion As Health Plans Add 1.1 Million Members

CVS lowered its earnings outlook due to costs associated with recent acquisitions.

CVS beats on earnings and revenue but lowers profit outlook

The health giant lowers earnings guidance for the full year.

CVS Health Stock Falls on Guidance Cut

Shares of CVS Health Corp. CVS gained 0.6% in premarket trading Wednesday, after the health care services and drug store chain reported a first-quarter profit beat and revenue that rose well above expectations, but cut its full-year earnings outlook. Net income fell to $2.14 billion, or $1.65 a share, from $2.36 billion, or $1.77 a share, in the year-ago period.

News for CVS Health Stock (CVS)